Breye Therapeutics
PrivateLast Round
Series A
Sep 29, 2026
Total Funding Raised
$79.9M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Breye Therapeutics is a biopharmaceutical company developing orally administered small-molecule therapies for the treatment of retinal vascular diseases such as diabetic retinopathy and age-related macular degeneration.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Breye Therapeutics Comparables
Compare Breye Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vantage Biosciences | 84% | |
| Rezolute, Inc. | 79% | |
| Opus Genetics | 77% |
Breye Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 29, 2026 | ||||
| Seed | Nov 10, 2022 |
Key People
Founding team and executive leadership
Breye Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Fund Denmark | Seed |
| Innovestor | Series A |
| Catalyze Capital | Series A |
| A. M. Pappas & Associates | Series A |
| Innovestor Life Science | Series A |
| Novo Holdings | Series A, Seed |
| The Export and Investment Fund of Denmark | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 29, 2026
$77M round led by Novo Holdings and Mission BioCapital.
- Nov 10, 2022
$4M round led by Novo Holdings and Sound Bioventures.
Recent news
Latest coverage and updates
- hiresSep 29, 2026
Breye Therapeutics ApS will appoint Robert Blazej, Partner at Mission BioCapital, to its board in Denmark on Oct 2nd '26
- hiresSep 29, 2026
Lukas Ljungström to join Breye Therapeutics ApS's board on Oct 1st '26
- receives_financingSep 29, 2026
Breye Therapeutics ApS closed an over-subscribed $76.8M Series A financing round in Denmark on Sep 29th '26, co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial and develop its retinal disease pipeline.
- is_developingSep 23, 2026
Breye Therapeutics ApS plans a randomized Phase 2 trial of danegaptide for NPDR in 2027
Breye Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Breye Therapeutics's valuation, stock price, and market status.
Is Breye Therapeutics a public or private company?
Breye Therapeutics is a private company.
What is the current stock price of Breye Therapeutics?
Breye Therapeutics is a private company, so its shares have no public market price. Caplight tracks Breye Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Breye Therapeutics worth (valuation)?
Valuation information for Breye Therapeutics is not publicly available.
Can I buy Breye Therapeutics stock?
Breye Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Breye Therapeutics's last funding round?
Breye Therapeutics's most recent funding round was Series A on September 29, 2026.
Who are the main investors in Breye Therapeutics?
Key investors in Breye Therapeutics include Novo Holdings, Mission BioCapital, Sound Bioventures.
Will Breye Therapeutics IPO soon?
No public IPO plans have been announced for Breye Therapeutics.
How can I track Breye Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Breye Therapeutics's shares on secondary markets.